SenesTech, Inc. (SNES)

SenesTech, Inc. (SNES) Materials & Commodity Exposure

SenesTech, Inc. (SNES) is a Basic Materials company specializing in specialty chemicals, developing innovative fertility control solutions for pest management. Its flagship product, ContraPest, offers a non-lethal approach to reducing rat populations, positioning the company in the evolving pest control market with a focus on sustainable and humane methods.

What Is the Investment Thesis for SNES?

SenesTech, Inc. presents an investment thesis centered on its proprietary fertility control technology, ContraPest, which addresses the increasing demand for non-lethal pest management solutions. The company's high gross margin of 63.4% indicates strong product-level profitability, suggesting potential for significant earnings leverage if sales volumes expand. Key growth catalysts include the ongoing shift in public and regulatory sentiment towards humane pest control, which could accelerate market adoption of ContraPest. Expanding the company's market reach through new distribution channels or geographic territories, particularly within commercial and governmental sectors, represents a significant value driver. However, the company faces considerable risks, including a negative Return on Equity of -128.0%, reflecting ongoing profitability challenges and a small market capitalization of $8.11M. Limited market adoption due to the entrenched nature of traditional pest control methods and intense competition pose ongoing challenges. Investors should monitor the company's ability to demonstrate sustained revenue growth and achieve positive net income, which are critical for long-term viability and shareholder value creation.

Based on FMP financials and quantitative analysis

SNES Key Highlights

• Market Capitalization: $0.01 billion, indicating a micro-cap company with potentially higher volatility and growth potential.
• Gross Margin: 63.4%, demonstrating strong profitability at the product level, suggesting efficient cost of goods sold for ContraPest.
• Return on Equity (ROE): -128.0%, highlighting significant net losses relative to shareholder equity, indicating current unprofitability.
• Debt-to-Equity (D/E) Ratio: 34.14, representing a moderate level of financial leverage.
• Beta: 0.29, suggesting lower volatility compared to the broader market, which may appeal to risk-averse investors.

Who Are SNES's Competitors?

SNES is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SNES's Key Strengths?

• Proprietary fertility control technology (ContraPest) offers a unique solution.
• Non-lethal approach aligns with growing demand for humane and sustainable pest control.
• High gross margin of 63.4% indicates strong product-level profitability.
• Addresses a significant global problem of pest overpopulation with an innovative method.

What Are SNES's Weaknesses?

• Limited market adoption compared to established traditional pest control methods.
• Negative Return on Equity (-128.0%) reflects ongoing net losses and profitability challenges.
• Small market capitalization ($0.01B) may limit access to capital and market visibility.
• Reliance on a single primary product (ContraPest for rats) for revenue generation.

What Could Drive SNES Stock Higher?

• Expansion of ContraPest into new geographical markets, particularly in regions with strong demand for humane pest control solutions.
• Successful penetration into new customer segments, such as large-scale agricultural operations or broader governmental contracts, driving increased sales volume.
• Increasing public and regulatory preference for humane and environmentally responsible pest control methods, creating a favorable market environment for ContraPest.
• Announcement of strategic partnerships with major pest management companies, facilitating wider distribution and adoption of SenesTech's technology.

What Are the Key Risks for SNES?

• Financial-distress signal — its Altman Z-Score of -17.89 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-76.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Limited market adoption of non-lethal solutions, as traditional pest control methods remain deeply entrenched and widely utilized.
• Sustained negative Return on Equity of -128.0%, indicating persistent challenges in achieving profitability and generating positive returns for shareholders.
• Intense competition from established pest control companies offering conventional, often lower-cost, solutions, potentially hindering market share growth.
• Regulatory hurdles or delays in obtaining necessary approvals for new product formulations or expanding target species, impacting market entry and growth.
• Capital constraints given the company's small market capitalization of $8.11M, which could limit investment in R&D, marketing, and operational scaling.

What Are the Growth Opportunities for SNES?

• Growth opportunity 1: Expanding market penetration for ContraPest in commercial and governmental sectors. The demand for non-lethal and environmentally responsible pest control solutions is growing among municipalities, public health organizations, and large commercial enterprises. By targeting these segments more aggressively, SenesTech can leverage its unique product offering to capture a larger share of the market. This expansion could involve securing larger contracts and demonstrating the long-term cost efficiencies of fertility control, potentially unlocking significant revenue streams within a several-year timeline.
• Growth opportunity 2: Increasing adoption of non-lethal pest control solutions driven by societal and regulatory shifts. There is a discernible global trend towards more humane and sustainable pest management practices, influenced by animal welfare concerns and environmental regulations. As public awareness grows and regulatory bodies potentially favor non-lethal methods, SenesTech's ContraPest could see accelerated market acceptance. This macro-trend provides a long-term tailwind, potentially expanding the addressable market significantly over the next five to ten years as traditional methods face increasing pressure.
• Growth opportunity 3: Strategic partnerships with established pest management companies. Collaborating with larger, incumbent pest control service providers could significantly accelerate ContraPest's market reach and distribution. These partnerships could provide SenesTech access to extensive customer bases, established sales channels, and operational expertise that would be challenging to build independently. Such alliances could lead to quicker market penetration and increased revenue generation within a 2-3 year timeframe, leveraging the partners' existing infrastructure.
• Growth opportunity 4: Development and commercialization of fertility control solutions for additional pest species. While ContraPest currently targets rats, the underlying technology or scientific principles could potentially be adapted to manage other pest animal populations. Expanding the product pipeline to include solutions for different species (e.g., other rodents, invasive birds) would open up entirely new market segments and diversify the company's revenue streams. This opportunity represents a longer-term growth driver, likely requiring significant R&D investment over a 3-5 year horizon.
• Growth opportunity 5: Leveraging high gross margins to fund market expansion and R&D. With a reported gross margin of 63.4%, SenesTech demonstrates strong unit economics for its product. This high margin provides a solid foundation for reinvestment into sales and marketing initiatives to drive broader adoption of ContraPest, as well as into research and development for new applications or species. Effectively utilizing this margin to scale operations and innovate can be a critical driver for achieving sustained profitability and market leadership over the next several years.

What Opportunities Does SNES Have?

• Growing societal and regulatory preference for humane and environmentally friendly pest control solutions.
• Expansion into new geographical markets and customer segments (e.g., large-scale agriculture, international).
• Strategic partnerships with larger pest management companies to leverage existing distribution networks.
• Potential to adapt fertility control technology for other pest species beyond rats.

What Threats Does SNES Face?

• Intense competition from well-established companies offering conventional, often cheaper, pest control methods.
• Potential for regulatory hurdles or delays in approvals for new products or expanded applications.
• Challenges in educating the market and overcoming skepticism towards a novel pest control approach.
• Capital constraints and funding challenges inherent to a small-cap company with ongoing losses.

What Are SNES's Competitive Advantages?

• Proprietary formulation and scientific expertise in fertility control for pest animals, specifically ContraPest.
• Differentiated non-lethal approach distinguishes it from conventional, often lethal, pest control methods.
• Potential for intellectual property protection through patents on its unique biological pest management technology.
• Specialized knowledge in reproductive biology and endocrinology applied to pest population management.

What Does SNES Do?

SenesTech, Inc., founded in 2004 and headquartered in Phoenix, Arizona, is a pioneering company dedicated to developing and commercializing innovative technologies for managing pest animal populations through fertility control. The company operates within the Basic Materials sector, specifically focusing on specialty chemicals that offer a differentiated approach to pest management. Its core product, ContraPest, is a specially formulated liquid bait designed to effectively reduce the breeding capacity of both male and female rats. This non-lethal solution stands in contrast to conventional pest control methods that often rely on lethal poisons or traps. Since its inception, SenesTech has evolved to address the growing demand for more humane and environmentally conscious pest control options. The company's technology aims to provide a sustainable long-term solution by targeting the reproductive capabilities of pests, thereby reducing their populations over time rather than through immediate extermination. This strategic focus places SenesTech in a unique market position, catering to commercial, governmental, and agricultural clients seeking advanced, responsible pest management strategies. With a relatively small team of 23 employees, the company emphasizes scientific research and product development to expand the application and reach of its fertility control solutions.

What Products and Services Does SNES Offer?

• Develop innovative technologies for managing pest animal populations.
• Focus on inhibiting the fertility of pests rather than lethal methods.
• Manufacture and commercialize ContraPest, a liquid bait.
• ContraPest is specifically designed to reduce the breeding capacity of rats.
• The product targets both male and female rat populations.
• Offer non-lethal, humane, and sustainable pest control solutions.
• Operate within the specialty chemicals segment of the Basic Materials sector.

How Does SNES Make Money?

• Generate revenue through the sale of ContraPest liquid bait.
• Sell products to commercial pest management operators.
• Supply governmental agencies and municipalities for public health initiatives.
• Target agricultural businesses and food processing facilities as end-users.
• Focus on recurring sales of bait for ongoing population management programs.

What Industry Does SNES Operate In?

SenesTech, Inc. operates within the Basic Materials sector, specifically the Specialty Chemicals industry, but its market application is firmly rooted in pest management. The broader pest control industry is experiencing a notable trend towards more environmentally friendly and humane solutions, driven by public demand and evolving regulatory landscapes. Traditional methods, often involving lethal chemicals or traps, face increasing scrutiny regarding their impact on non-target species and ecosystems. SenesTech positions itself as an innovator within this shifting paradigm, offering a non-lethal, fertility-inhibiting approach to pest control. While the overall pest control market is substantial, SenesTech occupies a niche segment, competing against well-established companies that primarily offer conventional solutions. The company's success hinges on its ability to educate the market and demonstrate the long-term efficacy and cost-effectiveness of its fertility control technology against entrenched traditional practices.

Who Are SNES's Key Customers?

• Commercial pest control service providers.
• Governmental entities, including public health departments.
• Municipalities and urban management programs.
• Agricultural enterprises seeking humane pest management.
• Food processing and storage facilities requiring stringent pest control.

SenesTech, Inc. (SNES) Valuation Context

Valued at $8.11M, SNES is classified as a micro-cap stock. Relative to its peer group, SNES's quantitative score of 16/100 is below the peer average of 64/100.

SNES Revenue & Earnings Trend

In Q1 2026, SNES generated $493K in top-line revenue, marking a sequential increase of 17.1%. The company recorded a net loss of $2.1M, with diluted EPS of $-0.39. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Basic Materials. Across the four most recent quarters, SNES averaged $-0.47 in diluted EPS.

Company Profile

SenesTech, Inc. operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in Phoenix, US. The company is led by CEO Joel L. Fruendt. SNES has traded publicly since 2016.

ROE -76%Key Financial Metrics

Return on equity for SenesTech, Inc. stands at -76.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -61.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -78.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -86.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

SenesTech, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.89 places it in the distress zone, a signal of elevated financial risk.

6/7 beatsEarnings Track Record

SenesTech, Inc. has beaten Wall Street's EPS estimate in 6 of its last 7 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 11.6% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project SenesTech, Inc. revenue of about $2.3M for fiscal 2026, with EPS near $-1.48.

Net buyingInsider Activity

Over the past six months, SenesTech, Inc. insiders filed 15 SEC Form 4 transactions — 0 sales and 15 purchases. On net that is roughly 284K shares acquired (about $547K) — insiders putting money in tends to read as conviction.

SNES Financials

SNES Latest News

SNES Analyst Consensus

SNES MoonshotScore

SenesTech, Inc. Basic Materials Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources